Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alza Corp.
Alza receives U.S. Food and Drug Administration approval for Ionsys for pain management
June 23rd, 2006
The U.S. Food and Drug Administration (FDA) has approved Ionsys (fentanyl iontophoretic transdermal system), a needle-free, patient-activated analgesic system. Ionsys is indicated for the short-term management of acute post-operative pain in adult patients requiring opioid analgesia during hospitalization. Ionsys is the first and only product to incorporate the E-Trans iontophoretic transdermal drug delivery system developed by Alza Corp. E-Trans utilizes iontophoresis - a process in which a low-intensity electric field, which is generally imperceptible to the patient, is used to rapidly transport fentanyl across the skin and into the circulatory...
Source: Biotech Law Weekly (2006-06-23)
|
